{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:29:15Z","timestamp":1786649355536,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Standard treatments available today for treating hypertension is diuretics, \u03b2-blockers, angiotensin converting enzyme inhibitors (ACEs), angiotensin receptor blockers (ARBs), calcium channel blockers, a-blockers, vasodilators, and centrally acting drugs. It is difficult to achieve the optimized renin angiotensin aldosterone system suppression with currently available antihypertensive agents, because ACE inhibitors, ARBs, and diuretics all activate the compensatory feedback mechanism that increases renin release and increase plasma renin activity. The first orally active direct renin inhibitors (DRIs) were developed in 1980s, including enalkiren, remikiren, and zankiren. However, poor absorption from the gastrointestinal tract, less bioavailability (&lt;2%), short half life, and low potency hindered the development of these compounds. Aliskiren is the first DRI for the treatment of hypertension. Aliskiren is designed through a combination of molecular modeling techniques and crystal structure elucidation. Aliskiren effectively reduces the blood pressure as a mono therapy as well in combination therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.93250","type":"journal-article","created":{"date-parts":[[2012,2,25]],"date-time":"2012-02-25T03:30:45Z","timestamp":1330140645000},"page":"32-38","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Aliskiren, the first direct renin inhibitor for treatment of hypertension"],"prefix":"10.4103","volume":"58","author":[{"given":"M","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Yeola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Zope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Nabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20250320","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: Analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"R2-6-20250320","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4103\/0971-5916.73420","article-title":"Surveillance of cardiovascular disease risk factors in India: The need and scope","volume":"132","author":"Shah","year":"2010","journal-title":"Indian J Med Res"},{"key":"R4-6-20250320","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10557-010-6232-1","article-title":"Application of direct renin inhibition to chronic kidney disease","volume":"24","author":"Mende","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"R5-6-20250320","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1161\/01.CIR.0000131449.94713.AD","article-title":"Combined blockade of the renin angiotensin system with angiotensin converting enzyme inhibitors and angiotensin II type I receptor antagonist","volume":"109","author":"Azizi","year":"2004","journal-title":"Circulation"},{"key":"R6-6-20250320","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","article-title":"Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with thiazide diuretics, an angiotensin converting enzyme inhibitor, or an angiotensin receptor blocker","volume":"49","author":"O'brien","year":"2007","journal-title":"Hypertension"},{"key":"R7-6-20250320","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","article-title":"Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system","volume":"32","author":"Hollenberg","year":"1998","journal-title":"Hypertension"},{"key":"R8-6-20250320","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0163-7258(94)90015-9","article-title":"Pharmacology of renin inhibitor and their application to the treatment of hypertension","volume":"61","author":"Wood","year":"1994","journal-title":"Pharmacol Ther"},{"key":"R9-6-20250320","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(06)69442-7","article-title":"Oral renin inhibitor","volume":"368","author":"Staesson","year":"2006","journal-title":"Lancet"},{"key":"R10-6-20250320","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2147\/VHRM.S11816","article-title":"Blocking the RAAS at different levels: An update on the use of the direct renin inhibitors alone and in combination","volume":"6","author":"Cagnoni","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"R11-6-20250320","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5301\/jn.5000008","article-title":"Aliskiren: The first direct rennin inhibitor available for clinical use","volume":"24","author":"Morganti","year":"2011","journal-title":"J of Nephrol"},{"key":"R14-6-20250320","first-page":"1569","article-title":"A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results","volume":"8","author":"Wood","year":"1997","journal-title":"Eur Heart J"},{"key":"R15-6-20250320","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/eurheartj\/ehq190","article-title":"Patients with acute coronary syndromes and elevated levels of natriuretic peptides: The results of the AVANT GARDE-TIMI 43 Trial","volume":"31","author":"Scirica","year":"2010","journal-title":"Eur Heart J"},{"key":"R16-6-20250320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/IJNRD.S6653","article-title":"Role of aliskiren in blood pressure control and renoprotection","volume":"4","author":"Trimarchi","year":"2011","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"R17-6-20250320","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/VHRM.S15541","article-title":"A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors","volume":"7","author":"Siragy","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"R18-6-20250320","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2550","article-title":"Aliskiren: The first renin inhibitor for clinical treatment","volume":"7","author":"Jensen","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"R19-6-20250320","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"R21-6-20250320","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.HYP.0000179573.91016.3f","article-title":"Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats","volume":"46","author":"Pilz","year":"2005","journal-title":"Hypertension"},{"key":"R22-6-20250320","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004872-200502000-00025","article-title":"Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats","volume":"23","author":"Wood","year":"2005","journal-title":"J Hypertens"},{"key":"R23-6-20250320","first-page":"984","article-title":"Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice","volume":"118","author":"Lu","year":"2008","journal-title":"J Clin Invest"},{"key":"R24-6-20250320","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1476-5381.2009.00355.x","article-title":"Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity","volume":"158","author":"Stucchi","year":"2009","journal-title":"Br J Pharmacol"},{"key":"R25-6-20250320","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"R26-6-20250320","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1470320308096411","article-title":"Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension","volume":"9","author":"Dietz","year":"2008","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R27-6-20250320","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"R28-6-20250320","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1470320309342407","article-title":"Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension","volume":"10","author":"Andersen","year":"2009","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R29-6-20250320","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation"},{"key":"R30-6-20250320","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren","volume":"42","author":"Stanton","year":"2003","journal-title":"Hypertension"},{"key":"R31-6-20250320","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/HYPERTENSIONAHA.106.084301","article-title":"Direct Renin inhibition with aliskiren in obese patients with arterial hypertension","volume":"49","author":"Jordan","year":"2007","journal-title":"Hypertension"},{"key":"R32-6-20250320","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.2004.02160.x","article-title":"Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects","volume":"58","author":"Dieterle","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R33-6-20250320","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201258010-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:53:02Z","timestamp":1786647182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201258010-00006"}},"subtitle":["The path of its development"],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.93250","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}